Antitrypanosomal activity against wild-type Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as cure from infection at 25 mg/kg, po for 4 days
Antitrypanosomal activity against wild-type Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as survival of mouse at 25 mg/kg, po for 4 days
Antitrypanosomal activity against wild-type Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as survival of mouse at 5 mg/kg, po for 4 days
Antitrypanosomal activity against Trypanosoma brucei brucei GVR35 infected in NMRI mouse CNS model assessed as survival of mouse at 100 mg/kg, po for 5 days
Antitrypanosomal activity against wild-type Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as cure from infection at 5 mg/kg, po for 4 days
Drug level in human liver microsomes treated with 10 uM DB868 prodrug after 180 mins incubation by HPLC-UV chromatography relative to initial prodrug concentration
Drug level in rat liver microsomes treated with 10 uM DB868 prodrug after 180 mins incubation by HPLC-UV chromatography relative to initial prodrug concentration
Drug metabolism in human liver microsomes assessed as (3Z,3'Z)-6,6'-(furan-2,5-diyl)bis(N'-hydroxynicotinimidamide) formation measured per mg of protein by HPLC-MS/MS analysis
Drug metabolism in human liver microsomes assessed as (3Z,3'Z)-6,6'-(furan-2,5-diyl)bis(N'-hydroxynicotinimidamide) formation measured by HPLC-MS/MS analysis